Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Sujet Principal
Gamme d'année
1.
China Pharmacy ; (12): 2370-2373, 2017.
Article Dans Chinois | WPRIM | ID: wpr-619050

Résumé

OBJECTIVE:To observe the clinical efficacy and safety of Xiaozhen zhiyang spray in the treatment of EGFRI-asso-ciated rash. METHODS:A total of 60 malignant tumor patients suffering from rash induced by EGFRI were divided into trial group (40 cases)and control group(20 cases)according to the patient's willingness. Control group didn't received any therapy for rash. Trial group received Xiaozhen zhiyang spray for several times a day according to the degree of rash as 1-2 times/d for first degree, 2-3 times/d for second degree,3-5 times/d for third degree,and the treatment course lasted for 2 weeks. Rash degree and improve-ment,itching degree and improvement,daily life quality index(DLQI)score before and after treatment as well as the occurrence of ADR were compared between 2 groups. RESULTS:before treatment,there was no statistical significance in rash and itching de-gree,or DLQI score between 2 groups(P>0.05). After treatment,rash and itching degree of trial group were improved significant-ly compared to before treatment and control group,with statistical significance(P0.05). No obvious ADR was found in trial group. CONCLUSIONS:Xiaozhen zhiyang spray can effectively relieve EGFRI-associated rash and itching as well as improve the quality of life for patients.

2.
Dermatol. argent ; 18(1): 18-29, ene.-feb. 2012. tab, ilus
Article Dans Espagnol | LILACS | ID: lil-724291

Résumé

Los inhibidores del receptor de factor de crecimiento epidérmico son un grupo de drogas nuevas usadas para el tratamiento de tumores en estadios avanzados. Estas drogas producen conmucha frecuencia toxicidad cutánea. El objetivo de este artículo es realizar una revisión de estas reacciones cutáneas y el manejo de las mismas.


Epidermal growth factor - receptor inhibitors constitute a new group of drugs used for the treatment of malignant tumors in advanced stages. These drugs produce with high frequency cutaneous toxicity. The aim of this paper is to review those cutaneous reactions, and their management.


Sujets)
Humains , Récepteurs ErbB/antagonistes et inhibiteurs , Antinéoplasiques/effets indésirables , Éruptions acnéiformes/étiologie , Toxidermies/étiologie , Peau/anatomopathologie
SÉLECTION CITATIONS
Détails de la recherche